Accounting Firms
RSM advises Celadon Pharmaceuticals on £80m reverse acquisition
The acquisition means Celadon Pharmaceuticals plc has become the first pharmaceutical medicinal cannabis company to be admitted to AIM
RSM UK has advised Celadon Pharmaceuticals plc on its £80m reverse acquisition of Vertigrow Technology Ltd.
You'll need to
subscribe to unlock this content. Already subscribed? Login?
